JP6676629B2 - 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物 - Google Patents

糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物 Download PDF

Info

Publication number
JP6676629B2
JP6676629B2 JP2017518943A JP2017518943A JP6676629B2 JP 6676629 B2 JP6676629 B2 JP 6676629B2 JP 2017518943 A JP2017518943 A JP 2017518943A JP 2017518943 A JP2017518943 A JP 2017518943A JP 6676629 B2 JP6676629 B2 JP 6676629B2
Authority
JP
Japan
Prior art keywords
diabetes
compound
pharmaceutical composition
alkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017518943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530182A5 (enExample
JP2017530182A (ja
Inventor
リン・ギャニオン
ブリジット・グルー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Prometic Pharma SMT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma SMT Ltd filed Critical Prometic Pharma SMT Ltd
Publication of JP2017530182A publication Critical patent/JP2017530182A/ja
Publication of JP2017530182A5 publication Critical patent/JP2017530182A5/ja
Application granted granted Critical
Publication of JP6676629B2 publication Critical patent/JP6676629B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017518943A 2014-10-10 2015-10-08 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物 Expired - Fee Related JP6676629B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062526P 2014-10-10 2014-10-10
US62/062,526 2014-10-10
PCT/CA2015/000531 WO2016054726A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Publications (3)

Publication Number Publication Date
JP2017530182A JP2017530182A (ja) 2017-10-12
JP2017530182A5 JP2017530182A5 (enExample) 2018-11-22
JP6676629B2 true JP6676629B2 (ja) 2020-04-08

Family

ID=55652427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518943A Expired - Fee Related JP6676629B2 (ja) 2014-10-10 2015-10-08 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物

Country Status (21)

Country Link
US (1) US10105331B2 (enExample)
EP (1) EP3203998B1 (enExample)
JP (1) JP6676629B2 (enExample)
KR (1) KR20170066614A (enExample)
CN (1) CN106999458B (enExample)
AR (1) AR102248A1 (enExample)
AU (1) AU2015330643B2 (enExample)
BR (1) BR112017007420A2 (enExample)
CA (1) CA2963276A1 (enExample)
DK (1) DK3203998T3 (enExample)
ES (1) ES2875336T3 (enExample)
IL (1) IL251392B (enExample)
MX (1) MX376872B (enExample)
PH (1) PH12017500662B1 (enExample)
PL (1) PL3203998T3 (enExample)
PT (1) PT3203998T (enExample)
RU (1) RU2723486C2 (enExample)
SG (1) SG11201702812PA (enExample)
TW (1) TWI699201B (enExample)
UY (1) UY36354A (enExample)
WO (1) WO2016054726A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
US10391073B2 (en) * 2014-11-12 2019-08-27 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
RU2005128501A (ru) * 2003-02-13 2006-04-27 Веллстат Терапьютикс Корпорейшн (Us) Соединение для лечения метаболических расстройств
CA2580370A1 (en) * 2004-09-15 2006-03-23 Gokhan S. Hotamisligil Reducing er stress in the treatment of obesity and diabetes
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
JP2012072136A (ja) * 2010-09-03 2012-04-12 Erina Co Inc 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
CA2816094A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Also Published As

Publication number Publication date
RU2017116106A3 (enExample) 2019-02-13
WO2016054726A1 (en) 2016-04-14
EP3203998A4 (en) 2018-06-20
CN106999458B (zh) 2021-04-13
EP3203998B1 (en) 2021-03-10
SG11201702812PA (en) 2017-05-30
ES2875336T3 (es) 2021-11-10
KR20170066614A (ko) 2017-06-14
US10105331B2 (en) 2018-10-23
IL251392A0 (en) 2017-05-29
AR102248A1 (es) 2017-02-15
EP3203998A1 (en) 2017-08-16
MX376872B (es) 2025-03-07
RU2017116106A (ru) 2018-11-12
TW201618763A (zh) 2016-06-01
PL3203998T3 (pl) 2021-09-27
MX2017004738A (es) 2017-08-10
AU2015330643A1 (en) 2017-05-04
UY36354A (es) 2016-06-01
PT3203998T (pt) 2021-06-07
PH12017500662B1 (en) 2022-08-19
RU2723486C2 (ru) 2020-06-11
IL251392B (en) 2020-11-30
CN106999458A (zh) 2017-08-01
PH12017500662A1 (en) 2017-10-02
AU2015330643B2 (en) 2020-05-14
TWI699201B (zh) 2020-07-21
US20170209399A1 (en) 2017-07-27
JP2017530182A (ja) 2017-10-12
BR112017007420A2 (pt) 2018-01-16
DK3203998T3 (da) 2021-05-31
CA2963276A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
AU2011356584B2 (en) Compounds and pharmaceutical compositions for uses in diabetes
TW202202139A (zh) 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重
JP6676629B2 (ja) 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物
WO2012090225A2 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
EP2120905A1 (en) Methods, compounds, and compositions for treating metabolic disorders and diabetes
US9499467B2 (en) Ortho-fluoro substituted compounds for the treatment of metabolic diseases
CN101668530A (zh) 激活irs-1和akt的方法
US9815777B2 (en) Metformin salts to treat Type2 diabetes
JP6360826B2 (ja) 肝機能改善法
CA2598491A1 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
HK1236421B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
CN106432026A (zh) 一类对糖尿病具有潜在治疗活性的化合物
WO2011075935A1 (zh) 二苯基乙烯类衍生物及其用途
US10450328B2 (en) Crystals of thiadiazole derivative DPP-IV inhibitors and uses thereof
WO2024079677A1 (en) Novel therapeutic molecule
HK40078244A (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
HK1120255A (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200312

R150 Certificate of patent or registration of utility model

Ref document number: 6676629

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees